Enhertu Approved in EU for Inoperable, Advanced Breast Cancer

Enhertu Approved in EU for Inoperable, Advanced Breast Cancer

284018

Enhertu Approved in EU for Inoperable, Advanced Breast Cancer

The European Commission has conditionally approved Enhertu (trastuzumab deruxtecan) for adults in the EU with inoperable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens. A conditional approval is granted when the benefits of a medication regulators say still requires additional data or testing are found to outweigh its potential risks. Such approval is given for therapies whose immediate availability fulfills an unmet medical need, as in the case of…

You must be logged in to read/download the full post.